Anti-Erythropoietin,cl 6E5 ZooMAb?Rbmono

Application

Anti-Erythropoietin, clone 6E5 ZooMAb, Cat. No. ZRB1366, a recombinant Rabbit Monoclonal Antibody that targets Erythropoietin and is tested in Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Erythropoietin in HUVEC and NIH 3T3 cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Erythropoietin in human kidney and rat kidney tissue sections.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

His-tagged full-length mature recombinant human Erythropoietin (without the signal peptide).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 6E5 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Erythropoietin.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Erythropoietin (UniProt: P01588; also known as Epoetin, EPO) is encoded the EPO gene (Gene ID: 2056) in human. EPO is an acidic glycoprotein that is synthesized with a signal peptide (aa 1-27) that is subsequently cleaved off in the endoplasmic reticulum and the mature protein undergoes glycosylation in the Golgi prior to its release. EPO is mainly produced by peritubular fibroblasts in the renal cortex and to some extent by the liver in adult mammals. In fetal and neonatal mammals, it produced in the liver. EPO is the principle regulator of red blood cell production by stimulating the division and differentiation of bone marrow erythroid progenitor cells in response to anemia and hypoxia. It is induced by ischemic preconditioning by activation of (HIF)-1alpha. It is reported to contribute to angiogenesis in response to ischemia through upregulation of VEGF/VEGFR. It binds to EPO receptor that leads to receptor dimerization and JAK2 activation that results in activation of specific downstream effectors, including STAT1 and STAT3. Endogenous EPO consists of three N-linked polysaccharide groups and one O-linked group. Although its glycosylation slightly reduces its biological activity but is shown to be essential for ensuring its prolonged circulation in the plasma. The N-glycans in its structure protect it from the action of proteases and in the modulation of its receptor binding affinity. Mutations in EPO gene can cause microvascular complications in type II diabetic subjects and erythrocytosis. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Bunn, HF (2013). Cold Spring Harb. Perspect. Med. 3(3); a011619).